Work

Abstract OT2-3-01: SGN-LIV1A: A phase 1 trial evaluating a novel antibody-drug conjugate in patients with LIV-1-positive breast cancer

Year: 2015

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.sabcs14-ot2-3-01

Authors: Andres Forero, Howard Burris III, Patricia LoRusso, Jennifer Specht, Kathy Miller, Monica Mita, Minetta C Liu, Shanu Modi, Lajos Pusztai, Django Sussman, Ana Kostic

Institutions: University of Alabama, Sarah Cannon Research Institute, The Barbara Ann Karmanos Cancer Institute, Seattle Cancer Care Alliance, University of Washington, Cedars-Sinai Medical Center, Mayo Clinic, Memorial Sloan Kettering Cancer Center, Yale University, Seagen (United States)

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2199018900

Cites:

Cited by:

Related to: 10